DEINOVE Strengthens Significantly Its International Intellectual Property and Confirms Its Value Creation Strategy

Regulatory News:

DEINOVE (Paris:ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria, announced having received 10 new patent grant agreements.

Patent family PF7: "Bacteria and uses thereof" received an initial agreement for issuance by the US Patent Office (USTPO)¹. This is a key patent for DEINOVE, which refers to the genomic diversity of Deinococcus conferring advantageous properties including metabolic properties (digestion and assimilation of various carbon sources, and production of various metabolites). This patent protects the production of compounds such as ethanol, proteins, enzymes, or drugs from Deinococcus.

DEINOVE has also obtained new grant agreements for five families of patents already issued in other geographical areas:

• PF2 "Use of bacteria for the production of bio-energy" granted in Canada², and already issued in six other areas including the United States, Europe, Eurasia, Ukraine, Australia, and South Africa;
• PF3 "Methods for isolating bacteria" in Australia³ (already issued in the United States and South Africa);
• PF5 "High performance metabolic bacteria" in Japan⁴ and Australia⁵ (already issued in the United States and South Africa);
• PF6 "Recombinant bacteria and the uses thereof for producing ethanol" granted in Japan⁶, China⁷, Australia⁸ and the Eurasian area⁹ (already issued in the United States, Ukraine, and South Africa);
• PF8 "Enzymes and uses thereof" in the United States¹⁰ (already issued in South Africa).

The DEINOVE patent portfolio includes 19 patent families protecting its technology platforms, development of selection methods for a wide variety of Deinococcus and related bacteria, their use in the production processes of various biobased products of interest, and their industrial applications.

"The patent protection of our assets and our technologies is a major element of our strategy as it strengthens our position in the partnerships we develop in various applications with industrial companies. We are investing significantly in this area to secure the creation of long-term value for our shareholders," said Emmanuel PETIOT, CEO of DEINOVE.

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro-factories" to produce high value-added products from non-food biomass. The Company’s primary markets are 2nd-generation biofuels (DEINOL) and bio-based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com

¹ Publication No. US2013045482

² Publication No. CA2704429

³ Publication No. AU2010205590

⁴ Publication No. JP2012526538

⁵ Publication No. AU2010247336

⁶ Publication No. JP2012526537

⁷ Publication No. CN102421890

⁸ Publication No. AU2010247330

⁹ Publication No. EA201101627

¹⁰ Publication No. US20130309730

View source version on businesswire.com: http://www.businesswire.com/news/home/20160218006264/en/